Last updated: August 26, 2026
Methacrylic acid is primarily an industrial monomer, not a standalone pharmaceutical excipient. Its pharmaceutical value comes from copolymers used in modified-release, enteric, taste-masking, and protective coatings. The most important downstream products are methacrylic acid-methyl methacrylate copolymers, including polymer systems sold under the Eudragit brand. Demand is therefore linked to oral solid-dose formulation activity rather than direct consumption of methacrylic acid in medicines.
No reliable public source reports a standalone global market size, price index, or revenue forecast for methacrylic acid used in pharmaceutical excipients. Producers generally report methacrylic acid within broader acrylics, monomers, or performance materials segments. The financial outlook is positive for pharmaceutical-grade polymer demand but remains exposed to industrial oversupply, feedstock volatility, environmental regulation, and substitution by alternative coating polymers.
What is methacrylic acid and how is it used in pharmaceuticals?
Methacrylic acid, CAS Registry Number 79-41-4, is an unsaturated carboxylic acid used mainly to manufacture acrylic and methacrylic polymers. Its pharmaceutical role is indirect.
| Attribute |
Information |
| Chemical name |
2-Methylpropenoic acid |
| CAS number |
79-41-4 |
| Formula |
C4H6O2 |
| Primary commercial role |
Monomer for acrylic and methacrylic polymers |
| Pharmaceutical role |
Structural component of coating and drug-delivery polymers |
| Typical dosage-form application |
Tablets, capsules, multiparticulates, pellets |
| Main value driver |
Polymer performance, not free methacrylic acid consumption |
| Key downstream brands |
Eudragit polymer families and equivalent methacrylate copolymers |
Methacrylic acid-containing polymers are used to control drug release by exploiting pH-dependent dissolution. Copolymers with higher methacrylic acid content can remain insoluble in gastric conditions and dissolve at higher intestinal pH. Formulators use these materials for enteric protection, delayed release, colon targeting, and taste masking.
The free monomer is not normally the intended functional ingredient in a finished drug product. Residual monomer control is therefore more important than direct dosage-form demand.
What pharmaceutical excipients contain methacrylic acid?
The largest pharmaceutical application is methacrylic acid copolymers used as film-forming and release-controlling excipients.
Methacrylic acid-methyl methacrylate copolymers
Common polymer grades differ by monomer ratio, molecular weight, dissolution threshold, and application:
| Polymer type |
Typical pharmaceutical function |
| Methacrylic acid-methyl methacrylate copolymer, lower acid content |
Delayed release at higher intestinal pH |
| Methacrylic acid-methyl methacrylate copolymer, higher acid content |
Enteric release in the small intestine |
| Methacrylic acid-ethyl acrylate copolymer |
Aqueous or organic coating systems, flexible films |
| Ammonium methacrylate copolymers |
Sustained-release matrix and membrane coatings |
| Poly(methacrylic acid-co-methyl methacrylate) systems |
Taste masking, enteric protection, and targeted release |
Röhm’s Eudragit portfolio is the best-known commercial reference point. Comparable products are offered by other excipient and pharmaceutical-polymer suppliers. The commercial market is concentrated at the specialized polymer level, while upstream methacrylic acid production is more diversified and industrial.
The most defensible market measurement is therefore the value of functional pharmaceutical polymers, not the tonnage of methacrylic acid consumed by drug manufacturers.
What is the FDA regulatory status of methacrylic acid?
Methacrylic acid does not have the regulatory profile of an active pharmaceutical ingredient. Its pharmaceutical status depends on whether it is present as a residual monomer, incorporated into an approved polymeric excipient, or used in a manufacturing process.
The FDA Inactive Ingredient Database is the principal public reference for excipient precedent in approved drug products. Listings generally identify the finished excipient or polymer system rather than treating free methacrylic acid as a routine formulation ingredient.[1]
Key regulatory points are:
- Methacrylic acid itself is not an FDA-approved drug substance.
- It has no standalone therapeutic exclusivity.
- It has no Orange Book listing as an active ingredient.
- It has no Paragraph IV litigation pathway as a chemical excipient.
- Pharmaceutical polymers containing methacrylic acid require control of residual monomers, impurities, extractables, and leachables.
- Drug-product sponsors must establish excipient suitability for the route, dose, formulation, and manufacturing process.
European regulators similarly assess excipient safety and quality through the finished excipient specification, toxicological package, manufacturing controls, and use level. The European Pharmacopoeia and other pharmacopoeial standards may apply to specific methacrylate copolymers, but monomer status should not be confused with the status of the finished polymer excipient.[2]
What patents protect methacrylic acid pharmaceutical applications?
The base chemical is a mature commodity and is not protected by meaningful composition-of-matter exclusivity. Patent value is concentrated in manufacturing methods, polymer architecture, coating systems, and drug-delivery applications.
| Patent layer |
Commercial relevance |
Expected strength |
| Methacrylic acid composition of matter |
None for the mature molecule |
Expired or immaterial |
| Production process |
Catalyst selection, feedstock conversion, purification, inhibitor control |
Moderate at process level |
| Copolymer composition |
Monomer ratios, molecular weight, crosslinking, functional groups |
Moderate to strong when narrowly claimed |
| Pharmaceutical coating |
Spray systems, aqueous dispersions, plasticizers, pore formers |
Moderate |
| Drug-specific formulation |
Polymer combined with a particular active ingredient |
Potentially strong but narrow |
| Manufacturing process |
Granulation, coating temperature, curing, solvent recovery |
Moderate |
| Quality controls |
Residual monomer, particle size, dissolution profile |
Usually difficult to enforce alone |
The most valuable intellectual property is typically not a patent on methacrylic acid. It is a patent on a particular polymer grade, coating formulation, delivery profile, or drug-polymer combination.
How does patent risk differ from generic-drug patent risk?
There is no conventional Paragraph IV risk for methacrylic acid as an excipient. Generic-drug competition can still create indirect patent exposure where a finished product relies on:
- A patented enteric coating system.
- A drug-specific delayed-release formulation.
- A polymer blend with a defined dissolution profile.
- A manufacturing process covered by an issued patent.
- A license restricted to a particular dosage form or territory.
A generic manufacturer can often avoid infringement by changing polymer ratios, coating weight, plasticizer selection, curing conditions, or release specifications. That design-around potential limits the durability of many formulation patents.
How many patents cover methacrylic acid pharmaceutical uses?
There is no meaningful single patent count without defining the jurisdiction, polymer family, assignee, claim type, and filing date. Patent databases contain large numbers of documents referring to methacrylic acid across adhesives, dental materials, coatings, contact lenses, superabsorbents, and drug delivery.
A commercially relevant freedom-to-operate review should separate:
- Expired process patents.
- Active polymer-composition claims.
- Active drug-specific formulation claims.
- Continuations and divisionals.
- National-phase applications.
- Patents assigned to excipient suppliers.
- Patents owned by drug-product sponsors.
Patent families should be assessed by live claims, not document count. A high number of published applications does not indicate a strong barrier if the relevant claims are expired, abandoned, geographically limited, or directed to a different polymer architecture.
What is the market size and financial trajectory for methacrylic acid?
Public financial data do not isolate pharmaceutical methacrylic acid demand. The molecule is sold into much larger industrial markets, including coatings, adhesives, acrylic resins, water treatment, dental materials, and superabsorbent or specialty polymer applications.
The financial trajectory has four distinct layers:
| Layer |
Financial profile |
| Upstream methacrylic acid |
Commodity or semi-commodity pricing; sensitive to feedstocks and capacity |
| Pharmaceutical-grade polymer |
Higher margins; qualification and documentation create switching costs |
| Coating technology |
Margin depends on formulation know-how and process performance |
| Drug-product application |
Value is captured by the finished dosage form, not the monomer supplier |
Methacrylic acid prices are influenced by acetone cyanohydrin or C4-based production economics, propylene and acetone costs, energy, freight, plant utilization, and regional capacity. Industrial demand weakness can pressure monomer prices even when pharmaceutical polymer demand remains stable.
Pharmaceutical polymer suppliers have better margin protection than upstream monomer producers because customers qualify excipient grades and may require extensive documentation. However, qualification does not eliminate substitution risk. A customer can shift to another methacrylate supplier or use a different coating technology if regulatory comparability and product performance are demonstrated.
Which companies supply methacrylic acid and related pharmaceutical polymers?
The supply chain includes large chemical manufacturers, specialty polymer companies, and excipient distributors.
Upstream producers
Major producers and regional suppliers have included companies such as:
- Mitsubishi Chemical Group.
- Röhm.
- BASF.
- Sumitomo Chemical.
- Regional Asian methacrylate manufacturers.
- Integrated methyl methacrylate and acrylic-material producers.
Company participation varies by plant, region, grade, and corporate reporting period. Not every producer sells pharmaceutical-grade material directly.
Pharmaceutical polymer suppliers
The specialized supplier set includes:
- Röhm, through the Eudragit portfolio.
- Other excipient companies offering methacrylate copolymer equivalents.
- Contract manufacturers producing custom coating dispersions.
- Regional distributors with pharmaceutical-quality documentation and technical support.
Röhm’s downstream position is commercially important because the Eudragit brand is embedded in formulation development, regulatory files, and technical literature. That creates switching costs beyond the chemical composition of the polymer.
What manufacturing and intellectual-property barriers affect supply?
The principal barriers are quality consistency and regulatory qualification rather than access to the basic monomer.
Manufacturing barriers
Pharmaceutical polymer production requires control of:
- Residual methacrylic acid and methyl methacrylate.
- Polymer molecular-weight distribution.
- Monomer conversion.
- Particle size and dispersion stability.
- Glass-transition temperature.
- Viscosity.
- Film formation.
- Dissolution at specified pH values.
- Microbial and elemental impurities.
- Batch-to-batch coating performance.
A supplier can produce a chemically similar copolymer but still fail customer qualification if the material changes tablet dissolution, coating adhesion, film flexibility, or storage stability.
Intellectual-property barriers
The main IP barriers involve:
- Polymer composition ranges.
- Aqueous dispersion technology.
- Plasticizer systems.
- Drug-release profiles.
- Multiparticulate coating methods.
- Manufacturing and curing processes.
- Drug-specific formulation claims.
Trade secrets can be as important as patents. Polymerization conditions, inhibitor systems, purification methods, dispersion stabilization, and scale-up parameters may not be fully disclosed in patent claims.
What competitive dynamics will shape the market through 2030?
The market is likely to develop along five lines.
1. Growth in modified-release products
Oral modified-release products remain the core demand driver. Methacrylate polymers are established in enteric and delayed-release formulations, where regulatory precedent reduces development risk.
2. Pressure from alternative polymers
Cellulose derivatives, polyvinyl acetate systems, povidone-based materials, lipid coatings, and other synthetic polymers compete with methacrylate excipients. Selection depends on dissolution performance, processing equipment, global regulatory status, and cost.
3. Higher documentation requirements
Sponsors increasingly require full traceability, elemental-impurity data, nitrosamine risk assessments, change-control commitments, and supply-continuity plans. These requirements favor established pharmaceutical excipient suppliers.
4. Regionalization of supply
Asia is central to monomer and polymer capacity growth. Western drug manufacturers may still prefer dual sourcing from suppliers with established regulatory documentation and local technical support.
5. Sustainability and solvent reduction
Aqueous polymer dispersions can reduce organic-solvent use. Suppliers with low-VOC coating technologies, efficient drying processes, and lower-energy manufacturing may capture share in new formulation projects.
What generic launch risks exist for methacrylic-acid-based formulations?
Generic entry risk is generally high for the excipient itself and variable for the finished product.
| Product situation |
Generic-entry risk |
| Conventional tablet using an off-patent methacrylate polymer |
High |
| Simple enteric coating with established regulatory precedent |
High to moderate |
| Drug-specific multiparticulate delivery system |
Moderate |
| Complex polymer blend with narrow dissolution profile |
Moderate to low |
| Patented coating process or release-control architecture |
Low until patent expiry or design-around |
| Product dependent on a single qualified excipient source |
Supply risk rather than patent risk |
Generic manufacturers can often purchase equivalent polymers from multiple suppliers. The more difficult cases involve complex release profiles where a change in polymer grade alters bioequivalence, dissolution, or stability.
What is the Orange Book status of methacrylic acid?
Methacrylic acid has no standalone Orange Book status. It is neither a listed drug product nor an active pharmaceutical ingredient with FDA exclusivity.
The relevant regulatory records are:
- FDA Inactive Ingredient Database entries for applicable excipients.
- Approved drug labels identifying coating or release-controlling excipients.
- Drug Master Files and supplier regulatory packages.
- Pharmacopoeial monographs.
- Product-specific patents listed for the finished drug, where applicable.
A methacrylic-acid-based excipient does not independently block an abbreviated new drug application. Any regulatory barrier arises from the finished drug’s formulation, bioequivalence requirements, manufacturing process, or listed patents.
What licensing deals and settlement agreements affect the market?
Public licensing and settlement activity is generally concentrated in finished drug products and proprietary delivery systems, not in the commodity methacrylic acid market. Excipient suppliers commonly provide technical licenses, supply agreements, quality agreements, and formulation support, but these arrangements are often private.
The commercially relevant contractual issues are:
- Territory and field-of-use restrictions.
- Single-source or dual-source supply.
- Change-notification periods.
- Regulatory support obligations.
- Minimum purchase commitments.
- Rights to custom polymer grades.
- Ownership of formulation improvements.
- Confidentiality around coating and process parameters.
No broad industry-wide settlement framework governs methacrylic acid use in pharmaceuticals.
Key Takeaways
- Methacrylic acid is mainly an industrial monomer, not a standalone pharmaceutical excipient.
- Pharmaceutical value is concentrated in methacrylic acid-containing copolymers used for enteric, delayed-release, sustained-release, and taste-masking coatings.
- No reliable public source discloses a standalone pharmaceutical methacrylic acid market size or revenue forecast.
- Upstream economics are cyclical and exposed to feedstock, energy, capacity, and environmental costs.
- Downstream pharmaceutical polymers command stronger margins because of qualification, technical support, and regulatory documentation.
- Methacrylic acid has no Orange Book listing, drug exclusivity, or Paragraph IV pathway.
- Patent risk is concentrated in polymer compositions, coating technologies, manufacturing processes, and drug-specific formulations.
- Generic-entry risk is high for conventional formulations and lower for complex release-control systems.
- The strongest commercial positions belong to suppliers with validated polymer grades, global regulatory support, and reliable dual-region manufacturing.
FAQs
Is methacrylic acid safe as a pharmaceutical excipient?
Free methacrylic acid is not generally used as the functional excipient in finished medicines. Safety assessment focuses on the approved polymer, residual monomer limits, impurities, and the drug product’s route and exposure.
Is Eudragit made from methacrylic acid?
Several Eudragit grades are methacrylic acid copolymers, often combined with methyl methacrylate, ethyl acrylate, or related methacrylate monomers. The exact composition and dissolution behavior depend on the grade.
Can methacrylic acid polymers be replaced by cellulose polymers?
In some formulations, yes. Hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, cellulose acetate phthalate, and polyvinyl acetate systems can provide alternative enteric or controlled-release performance. Substitution requires formulation, dissolution, stability, and regulatory evaluation.
Does methacrylic acid have a pharmaceutical Drug Master File?
Suppliers may maintain Drug Master Files or equivalent confidential regulatory packages for methacrylate polymers and manufacturing processes. The existence and scope of a specific file depend on the supplier and product grade.
Is methacrylic acid demand correlated with drug sales?
Only partly. Pharmaceutical demand is linked to modified-release and enteric dosage-form development, but total methacrylic acid demand is driven primarily by industrial markets such as coatings, adhesives, acrylic resins, dental materials, and specialty polymers.
References
-
U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
-
European Medicines Agency. (2007). Guideline on excipients in the dossier for application for marketing authorisation of a medicinal product. https://www.ema.europa.eu/
-
National Center for Biotechnology Information. (n.d.). PubChem compound summary: Methacrylic acid. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Methacrylic-acid
-
Röhm GmbH. (n.d.). Eudragit pharmaceutical polymers. https://www.eudragit.com/
-
U.S. Food and Drug Administration. (2023). Drug Master Files guidance for industry. https://www.fda.gov/
-
United States Pharmacopeial Convention. (n.d.). United States Pharmacopeia and National Formulary. https://www.usp.org/
